clinical research prime

Intranasal RSV

24-59 months of age
A Phase 1/2a Trial of the Safety, Tolerability and Immunogenicity of PIV5-vectored RSV Vaccine in RSV Seropositive Children.
Participants will receive study related treatment at no cost and will be compensated for time and travel

Patient Info *

First

Last

Date of Birth *

Parent/Guardian Info *

First

Last

Phone *

Email *

Has child received a positive RSV, Influenza or SARS-Cov-2 diagnosis in the last 3 months? *

Does child have a history of wheezing or receipt of bronchodilator therapy? *

Is anyone in the household pregnant? *

Preferred Language

How did you hear about us? *

Please review my questions and contact me with further information for this study. *

A Phase 3 study to investigate the safety, tolerability, and immunogenicity of revaccinating pregnant women during subsequent pregnancies.
Participants will receive study related prevention at no cost and will be compensated for time and travel.

Patient Info *

First

Last

Date of Birth *

Phone *

Email *

Do you have a confirmed receipt of a single dose of RSVpreF (Abrysvo) in previous pregnancy? *

Are you currently pregnant? *

Preferred Language

How did you hear about us? *

Please review my questions and contact me with further information for this study. *

IDAHO FALLS

Monday-Thursday 8am-5pm & Friday 8am-2pm

187 East 13th Street
Idaho Falls, ID 83404

Clinical Research Prime is an Affiliate of Mountain View Hospital.

REXBURG

By Appointment Only
420 E 4th N
Rexburg, ID 83440

Call: (208) 497-0600
Text: (208) 508-1467
Fax: (208) 497-0606

SOCIAL MEDIA